DYRK1B and cancer: Pharmacological inhibition of Dyrk1B with RO5454948 inhibitor in the ovarian cancer cell lines TOV21G, SKOV3, and OVCAR3 similarly resulted in a selective effect on G0-quiescent cancer cells by promoting cell cycle re-entry, increased apoptosis, ROS levels, and DNA damage [36].